Portage Biotech Overview
Latest P/E ratio for Portage Biotech: -0.02 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-0.02
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for PRTG is -0.02. That is below the Energy sector average of 19.64. Investors often review this figure alongside Portage Biotech's historical trend and sector peers before judging valuation or financial health.
Against Energy companies, PRTG currently prints -0.02 for P/E ratio, while the sector average sits near 19.64. That is roughly 100.1% below the sector mean. Large gaps often invite a closer look at Portage Biotech's growth, margins, and balance sheet.
A P/E ratio of -0.02 for Portage Biotech is not 'good' or 'bad' on its own. Compare it with the peer average (19.64) and with PRTG's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting PRTG's P/E ratio (-0.02), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Portage Biotech's P/E ratio against similar Energy names. You can also browse sector and industry screens on Stockcircle for a broader set of Energy companies and their key multiples and fundamentals.
